{"filing":{"accession_number":"0001477932-26-004714","cik":"0001464165","ticker":"BETRF","company_name":"BetterLife Pharma Inc.","form":"6-K","filing_date":"2026-08-05","report_date":"2026-08-03","primary_document":"betrf_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1464165/000147793226004714/betrf_6k.htm"},"events":[{"id":24866,"run_id":22541,"accession_number":"0001477932-26-004714","anchor_item_number":"EX-99.1","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"This Material Change Report discloses multiple distinct events: (1) a strategic pivot of BETR-001 from psychiatric to migraine/headache indications with advancement to IND filing in 1Q 2027; (2) appointment of John W. LaRocca as director and audit committee member; (3) warrant and stock option exercises generating $352,500 in proceeds; and (4) convertible debenture conversion. The dominant disclosure is the clinical-development milestone and strategic repositioning of the lead asset, which is material to investors' assessment of the company's pipeline and regulatory trajectory, but this does not fit neatly into `earnings_release`, `exec_appointment` (though LaRocca's appointment is included), or other discrete event types. The exhibit bundles governance, operational, and financial events without a single dominant material event, making `other_material` the most appropriate classification.","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-08-05","form":"6-K","submitted_at":null,"items":[{"id":25557,"accession_number":"0001477932-26-004714","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This Material Change Report discloses multiple distinct events: (1) a strategic pivot of BETR-001 from psychiatric to migraine/headache indications with advancement to IND filing in 1Q 2027; (2) appointment of John W. LaRocca as director and audit committee member; (3) warrant and stock option exercises generating $352,500 in proceeds; and (4) convertible debenture conversion. The dominant disclosure is the clinical-development milestone and strategic repositioning of the lead asset, which is material to investors' assessment of the company's pipeline and regulatory trajectory, but this does not fit neatly into `earnings_release`, `exec_appointment` (though LaRocca's appointment is included), or other discrete event types. The exhibit bundles governance, operational, and financial events without a single dominant material event, making `other_material` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:31:25.987687+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25557,"accession_number":"0001477932-26-004714","item_number":"EX-99.1","item_title":"betrf_ex991.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"This Material Change Report discloses multiple distinct events: (1) a strategic pivot of BETR-001 from psychiatric to migraine/headache indications with advancement to IND filing in 1Q 2027; (2) appointment of John W. LaRocca as director and audit committee member; (3) warrant and stock option exercises generating $352,500 in proceeds; and (4) convertible debenture conversion. The dominant disclosure is the clinical-development milestone and strategic repositioning of the lead asset, which is material to investors' assessment of the company's pipeline and regulatory trajectory, but this does not fit neatly into `earnings_release`, `exec_appointment` (though LaRocca's appointment is included), or other discrete event types. The exhibit bundles governance, operational, and financial events without a single dominant material event, making `other_material` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-07T02:31:25.987687+00:00","company_name":"BetterLife Pharma Inc.","ticker":"BETRF","filing_date":"2026-08-05"}]}